

Contents

<i>F. M. Muggia, J. Henney, and V. DeVita, Jr.:</i> General Progress in Clinical Chemotherapy of Advanced Disease	1
<i>G. Bonadonna, M. Gasparini, and A. Rossi:</i> Adjuvant Therapies of Postsurgical Minimal Residual Disease	8
<i>S. Garattini:</i> Limits of Animal Models in Cancer Chemotherapy	26
<i>S. K. Carter:</i> Clinical Chemotherapy: Its Correlation with Experimental Models	31
<i>R. C. Donehower:</i> Metabolic Conversion of Methotrexate in Man	37
<i>W. Wilmanns, H. Sauer, and A. Schalhorn:</i> Biochemical Control of High-Dose Methotrexate/ Leucovorin Rescue Therapy	42
<i>F. A. Greco, K. R. Hande, R. L. Richardson, and R. K. Oldham:</i> High-Dose Methotrexate in Combination Chemotherapy for Small Cell Lung Cancer	50
<i>B. Fernbach, I. Takahashi, T. Ohnuma, and J. F. Holland:</i> Clinical and Laboratory Reevaluation of Dichloromethotrexate	56
<i>C. Erlichman:</i> An Overview of the Clinical Pharmacology of N-Phosphonacetyl-L-Aspartate (PALA), a New Antimetabolite	65
<i>M. Rozencweig, R. Abele, M. Piccart, D. D. Von Hoff, and F. M. Muggia:</i> N-(Phosphonacetyl)-L-Aspartate (PALA):Current Status	72

<i>M. Bobek, Y.-C. Cheng, E. Mihich, and A. Bloch:</i> Synthesis, Biologic Effects, and Biochemical Properties of Some 2'-Azido- and 2'-Amino- 2'-Deoxyarabinofuranosyl Pyrimidines and Purines	78
<i>B. Ardalan, J. Macdonald, D. Cooney, M. Lippman, and P. Schein:</i> Prediction of Clinical Response to 5-Fluorouracil- Containing Chemotherapy: Preliminary Results of in Vitro Assay in Human Breast Cancer	84
<i>M. Bayssas, J. Gouveia, F. de Vassal, J.-L. Misset, L. Schwarzenberg, P. Ribaud, M. Musset, C. Jasmin, M. Hayat, and G. Mathé:</i> Vindesine: A New Vinca Alkaloid	91
<i>N. I. Nissen, P. Dombernowsky, H. H. Hansen, and A. G. Pedersen:</i> The Epipodophyllotoxin Derivatives VM-26 and VP-16-213, 1976-1979, a Review	98
<i>C. Paoletti, J.-B. Le Pecq, N. Dat-Xuong, P. Juret, H. Garnier, J.-L. Amiel, and J. Rouesse:</i> Antitumor Activity, Pharmacology, and Toxicity of Ellipticines, Ellipticinium, and 9-Hydroxy Derivatives: Preliminary Clinical Trials of 2-Methyl-9-Hydroxy Ellipticinium (NSC 264-137)	107
<i>D. S. Alberts, S. Y. Chang, H.-S. G. Chen, B. J. Larcom, and T. L. Evans:</i> Comparative Pharmacokinetics of Chlorambucil and Melphalan in Man	124
<i>F. M. Muggia, M. Rozencweig, and J. Penta:</i> Clinical Implications of Cisplatin Pharmacology	132
<i>M. Hayat, G. Brulé, P. Cappelaere, A. Cattan, J. Chauvergne, B. Clavel, J. Guerrin, J. L. Misset, E. Pommatau, P. Ribaud, F. M. Muggia, M. Rozencweig, and G. Mathé:</i> Cisplatinumdiamminodichloride (CPDD) in Chemotherapy of Cancers: A Phase II Therapeutic Trial	139
<i>J. H. Burchenal, G. Irani, K. Kern, L. Lokys, and J. Turkevich:</i> 1,2-Diaminocyclohexane Platinum Derivatives of Potential Clinical Value	146
<i>P. Ribaud, D. P. Kelsen, N. Alcock, E. Garcia-Giralt, P. Dubouch, C. C. Young, F. M. Muggia, J. H. Burchenal, and G. Mathé:</i> Preclinical and Phase I Studies of Malonatoplatinum	156

Contents	IX
<i>S. Oka:</i> A Review of Clinical Studies of Pepleomycin	163
<i>R. Maral, D. Heusse, F. Lavelle, G. Cueille, M. Marlard, C. Jacquillat, J. Maral, M.-F. Auclerc, M. Weil, G. Auclerc, and J. Bernard:</i> Experimental and Clinical Activity of a New Anthracycline Derivative: Detorubicin (14-Diethoxyacetoxydaunorubicin)	172
<i>EORTC Clinical Screening Group:</i> Clinical Study of Detorubicin	184
<i>V. Bonfante, G. Bonadonna, F. Villani, and A. Martini:</i> Preliminary Clinical Experience with 4'-Epidoxorubicin in Advanced Human Neoplasia	192
<i>H. Cortés-Funes, A. Brugarolas, and M. Gosálvez:</i> Quelamycin: A Summary of Phase I Clinical Trials . . .	200
<i>T. Oki, T. Takeuchi, S. Oka, and H. Umezawa:</i> Current Status of Japanese Studies with the New Anthracycline Antibiotic Aclacinomycin A	207
<i>G. Mathé, M.-A. Gil, M. Delgado, M. Bayssas, J. Gouveia, P. Ribaud, D. Machover, J.-L. Misset, F. de Vassal, L. Schwarzenberg, C. Jasmin, and M. Hayat:</i> Phase II Trial of Aclacinomycin in Acute Leukemia and Lymphosarcoma	217
<i>D. Dantchev, V. Slioussartchouk, M. Paintrand, C. Bourut, M. Hayat, and G. Mathé:</i> Ultrastructural Study of the Cardiotoxicity and Light- Microscopic Findings of the Skin After Treatment of Golden Hamsters with Seven Different Anthracyclines	223
<i>M. Rozencweig, D. D. Von Hoff, S. S. Legha, R. L. Csyk, and F. M. Muggia:</i> m-AMSA: A New Anticancer Agent	250
<i>D. L. Kisner, R. Catane, and F. M. Muggia:</i> The Rediscovery of DON (6-Diazo-5-oxo- L-norleucine)	258
<i>J. L. Speyer and C. E. Myers:</i> The Use of Peritoneal Dialysis for Delivery of Chemotherapy to Intraperitoneal Malignancies	264
<i>N. Brock:</i> The Development of Mesna for the Inhibition of Urotoxic Side Effects of Cyclophosphamide, Ifosfamide, and Other Oxazaphosphorine Cytostatics	270

<i>P. Lelieveld, J. H. Mulder, M. B. Edelstein, and</i>	
<i>L. M. van Putten:</i>	
Cell Kinetic Factors, Single Drugs and Combination	279
<i>D. L. Kisner and B. J. Lewis:</i>	
Hyperthermia and Chemotherapy: Preclinical	
Considerations	285
<i>D. S. Alberts, H.-S. G. Chen, S. Y. Chang, and Y. M. Peng:</i>	
The Disposition of Intraperitoneal Bleomycin,	
Melphalan, and Vinblastine in Cancer Patients	293
<i>S. E. Salmon, D. S. Alberts, B. G. M. Durie,</i>	
<i>F. L. Meyskens, S. E. Jones, B. Soehnlen, H.-S. G. Chen,</i>	
<i>and T. Moon:</i>	
Clinical Correlations of Drug Sensitivity in the Human	
Tumor Stem Cell Assay	300
<i>F. M. Muggia and J. Ziegler:</i>	
Comments on the Carcinogenic, Mutagenic, and	
Teratogenic Properties of Anticancer Drugs	306
<i>J. Ziegler and F. M. Muggia:</i>	
Long-Term Sequelae of Cancer Chemotherapy	312